Figure 1. The genomic landscape of FGFR3 mutant urothelial cancer.

(A) Oncoprint showing co-alterations of selected cancer-associated genes among patients with urothelial carcinoma whose tumor harbored FGFR2/3 alterations eligible for treatment with erdafitinib in the metastatic setting, stratified by disease state. (B) Lollipop plot depicting the spectrum of oncogenic FGFR3 mutations observed in 1,507 urothelial carcinoma tumors. (C) Volcano plot of selected genes co-altered with FGFR3, comparing alterations of tumors with versus without FGFR3 alteration. (D) Frequency of select co-altered genes among FGFR3-altered tumors as a function of primary site (bladder versus UTUC) and disease state.

Alt, altered; Mb, megabase; MIBC, muscle-invasive bladder cancer; Mut, mutations; NMIBC, non-muscle invasive bladder cancer; No., number; RTK, receptor tyrosine kinase; Sig, significant; TM, transmembrane; TMB, tumor mutational burden; UTUC, upper tract urothelial carcinoma.

†Hypermutated tumor with TMB of 409 mutations/megabase.

* p < .05

** p < .01